Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2014 · 10-Q
Revenue$29.68M$29.68M+10,460.5% vs Q2 2013 Net Income$3.20M$3.20MN/M vs Q2 2013 EPS Diluted$0.08$0.08N/M vs Q2 2013 Operating Income$3,756,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,058,000N/M Margins · derivedOperating margin12.7%+5521.2 pt vs Q2 2013
Net margin10.8%+9746.4 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 12, 2014 · 43 d after period end